{"entity":{"id":"nct06662786","kind":"trial","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","aka":["OrigAMI-2"],"tldr":"A phase 3 trial of Amivantamab, Cetuximab, Leucovorin (folinic acid) and Oxaliplatin in colorectal cancer, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer is a phase 3 interventional study registered as NCT06662786 by Janssen Research & Development, LLC, with 1000 participants planned, started 2024-10-18 and due to reach its primary completion in 2028-12-15. Interventions recorded: Amivantamab, Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin and Irinotecan Hydrochloride.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06662786","url":"https://clinicaltrials.gov/study/NCT06662786"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["bispecific-antibody","monoclonal-antibody"],"targets":[],"drugs":["amivantamab","cetuximab","leucovorin","oxaliplatin"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06662786","phase":"3","setting":"A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","sponsor":"Janssen Research & Development, LLC","participation":[{"nct":"NCT06662786","source":"https://clinicaltrials.gov/study/NCT06662786","fetchedAt":"2026-10-07T16:54:53.335Z","studySha256":"8979f52fa93ac3aca11f3ff06b1a4e601da39555cfada33caae46ccab1bdfb6f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Janssen Research & Development, LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1000,"enrolmentType":"ESTIMATED","siteCount":239,"recruitingSiteCount":233,"countries":["Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Israel","Italy","Japan","Malaysia","Netherlands","Poland","Puerto Rico","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-10-18","startedType":"actual","enrolled":1000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06662786/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}